WeTrials
Recruiting

A Pilot Clinical Trial of Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, Radioactive Iodine (RAI) Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma Patients Undergoing Initial RAI Therapy

What is this study?

This study tests if two targeted cancer drugs, vemurafenib and cobimetinib, can help prepare high-risk thyroid cancer patients for radioactive iodine treatment. The goal is to make the cancer cells more responsive to the iodine therapy so it works better to destroy them.

Who can participate?

You may be able to join if you are 18 or older, have been diagnosed with high-risk papillary, follicular, or Hurthle cell thyroid cancer with a specific gene change called BRAFV600E, and have not yet received radioactive iodine treatment.

What will happen?

Participants will take the study medications, undergo radioactive iodine therapy, and have regular check-ups, scans, and imaging tests for about 14 months to monitor their health.

Where and when?

This study is currently recruiting participants and takes place in Duarte, California, United States.

Key Points
  • 1Tests a combination of two targeted drugs before standard radioactive iodine therapy.
  • 2Designed for adults with high-risk thyroid cancer and a specific gene mutation.
  • 3Involves about 14 months of follow-up visits and imaging scans.

Related links

Outside pages about this study, checked by our team

Suggest a link
Conditions Studied
This study is investigating treatments for the following conditions
Thyroid Gland Follicular CarcinomaThyroid Gland Oncocytic CarcinomaThyroid Gland Papillary Carcinoma

This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.